Loading…
Lobbying Spend
—
Filings
51
Firms Hired
3
Active Period
2017–2023
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Donald Payne Sr. Colorectal Cancer Detection Act of 2021
2022 · fourth_quarter · Firm: STEWART STRATEGIES AND SOLUTIONS, LLC
H.R. 1655 (Donald Payne Sr. Colorectal Cancer Detection Act of 2021), to amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, to increase participation in colorectal cancer screening in under-screened communities of color, to offset the COVID-19 pandemic driven declines in colorectal cancer screening and for other purposes.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1655
Donald Payne Sr. Colorectal Cancer Detection Act of 2021
2022 · third_quarter · Firm: STEWART STRATEGIES AND SOLUTIONS, LLC
H.R. 1655 (Donald Payne Sr. Colorectal Cancer Detection Act of 2021), to amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, to increase participation in colorectal cancer screening in under-screened communities of color, to offset the COVID-19 pandemic driven declines in colorectal cancer screening and for other purposes.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1655
Donald Payne Sr. Colorectal Cancer Detection Act of 2021
2022 · second_quarter · Firm: STEWART STRATEGIES AND SOLUTIONS, LLC
H.R. 1655 (Donald Payne Sr. Colorectal Cancer Detection Act of 2021), to amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, to increase participation in colorectal cancer screening in under-screened communities of color, to offset the COVID-19 pandemic driven declines in colorectal cancer screening and for other purposes.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1655
Donald Payne Sr. Colorectal Cancer Detection Act of 2021
2022 · first_quarter · Firm: STEWART STRATEGIES AND SOLUTIONS, LLC
H.R. 1655 (Donald Payne Sr. Colorectal Cancer Detection Act of 2021), to amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, to increase participation in colorectal cancer screening in under-screened communities of color, to offset the COVID-19 pandemic driven declines in colorectal cancer screening and for other purposes.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1655
Donald Payne Sr. Colorectal Cancer Detection Act of 2021
2021 · fourth_quarter · Firm: STEWART STRATEGIES AND SOLUTIONS, LLC
H.R. 1655, to amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, to increase participation in colorectal cancer screening in under-screened communities of color, to offset the COVID-19 pandemic driven declines in colorectal cancer screening and for other purposes. H.R. 5376, Build Back Better Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1655
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: STEWART STRATEGIES AND SOLUTIONS, LLC
H.R. 1655, to amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, to increase participation in colorectal cancer screening in under-screened communities of color, to offset the COVID-19 pandemic driven declines in colorectal cancer screening and for other purposes. H.R. 5376, Build Back Better Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5376
Donald Payne Sr. Colorectal Cancer Detection Act of 2021
2021 · third_quarter · Firm: STEWART STRATEGIES AND SOLUTIONS, LLC
H.R. 1655, to amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, to increase participation in colorectal cancer screening in under-screened communities of color, to offset the COVID-19 pandemic driven declines in colorectal cancer screening and for other purposes. H.R. 5376, Build Back Better Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1655
Inflation Reduction Act of 2022
2021 · third_quarter · Firm: STEWART STRATEGIES AND SOLUTIONS, LLC
H.R. 1655, to amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, to increase participation in colorectal cancer screening in under-screened communities of color, to offset the COVID-19 pandemic driven declines in colorectal cancer screening and for other purposes. H.R. 5376, Build Back Better Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5376
Donald Payne Sr. Colorectal Cancer Detection Act of 2021
2021 · second_quarter · Firm: STEWART STRATEGIES AND SOLUTIONS, LLC
H.R. 1655, to amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, to increase participation in colorectal cancer screening in under-screened communities of color, to offset the COVID-19 pandemic driven declines in colorectal cancer screening and for other purposes.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1655
Donald Payne Sr. Colorectal Cancer Detection Act of 2021
2021 · first_quarter · Firm: STEWART STRATEGIES AND SOLUTIONS, LLC
H.R. 1655, To amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, to increase participation in colorectal cancer screening in under-screened communities of color, to offset the COVID-19 pandemic driven declines in colorectal cancer screening and for other purposes.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1655
Source: Senate LDA